The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

13 Nov 2019 07:00

RNS Number : 1857T
Ideagen PLC
13 November 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

13 November 2019

Ideagen PLC

("Ideagen" "the Company" or "the Group")

Trading Update

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2019.

The Board is pleased to report that trading has remained strong in the first half of the financial year and that revenue and EBITDA are both expected to be significantly ahead of the same period last year and in line with management's expectations. This has been achieved through both organic revenue growth and the acquisitions of Redland Business Solutions Ltd (acquired in June 2019) and Optima Diagnostics Ltd (acquired in Oct 2019). The Company has a clear strategy to grow revenues organically and maintain high EBITDA margins whilst transitioning from a perpetual licence to a SaaS based subscription model. The successful execution of this strategy will provide an even more robust business model and a higher quality of earnings over the medium term without impacting on the short-term profitability of the business.

The Board considers that the key growth metric for the Group is based on Annual Recurring Revenue ("ARR"). ARR is the value of the Group's contracted recurring revenue book at any point in time, which will be recognised over the next 12 month period.

The Group's ARR has grown by approximately 20 per cent. from £36.4 million on 30 April 2019 to £43.9 million on 31 October 2019. This comprises of acquisition-led growth of £3.8 million combined with organic growth of £3.7 million within the period, representing approximately a 20 per cent. organic growth rate on an annualised basis. Group performance is based on strong customer demand and sales execution in the period and indicates that the transition to a recurring model is progressing successfully and is ahead of schedule.

Total organic revenue growth in the period was 7 per cent. which, in the context of an accelerated SaaS transition, represents a strong performance. Recognised Recurring revenue is expected to be approximately 74 per cent. of total revenue and is expected to rise to over 80 per cent. in the next full financial year.

The Company continues to compete and win new business within the UK and international markets reflecting the Company's global expansion. During the period, the Company won over 240 new customer logos including Emirates Airline, Emirates Catering, Alexander Hall, Mallinckrodt Pharmaceuticals, Freightliner, Vietjet Air, Mylan Pharmaceuticals and Royal London.

At the period end the group had net debt of £18.2 million (30 April 2019: net debt of £1.3 million) after spending £19.8 million on acquisitions. Operating cash generation in the period remained robust and in line with the Board's expectations. 

Ben Dorks, Chief Executive Officer of Ideagen, commented:

"I am pleased to report an excellent start to Ideagen's financial year. Our core markets are strong and underpin the demand we have seen this half. We continue to execute our strategy, delivering growth and investing in the business whilst tightly managing the cost base. The Company has continued to make acquisitions which have further enhanced our global reach, customer base and product capability.

Cash generation has been good which coupled with further growth in new SaaS recurring revenues and an increase in repeat business from our growing customer base provides a strong platform for the second half.

The market opportunity remains large and long term and given the Group's position as a leader in the Governance, Risk and Compliance market, the Board is optimistic about the Group's continued growth prospects."

 Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

Ben Dorks, Chief Executive Officer

Graeme Spenceley, Chief Financial Officer

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson (Nomad)

Alice Lane (ECM)

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

Richard Andrews

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVLLFFKFFZFBE
Date   Source Headline
10th Aug 201711:45 amRNSDirector Dealing
28th Jul 20174:19 pmRNSDirector Dealing
18th Jul 20177:00 amRNSFinal Results
12th Jun 20178:45 amRNSHolding(s) in Company
18th May 20173:19 pmRNSExercise of Options and Total Voting Rights
17th May 20177:00 amRNSPre-Close Trading Update
11th May 20172:21 pmRNSHolding(s) in Company
31st Mar 20171:10 pmRNSDirector/PDMR Shareholding
30th Mar 201711:48 amRNSHolding(s) in Company
30th Mar 20177:00 amRNSNew Aviation SaaS contracts worth £1.8m
28th Mar 20179:16 amRNSHolding(s) in Company
27th Mar 20176:05 pmRNSHolding(s) in Company
23rd Mar 201710:49 amRNSDirectors' Dealing & Total Voting Rights
23rd Mar 20177:00 amRNSAcquisition and Placing to raise £10m
1st Mar 201711:47 amRNSExercise of Options and Total Voting Rights
1st Mar 20177:00 amRNSHolding(s) in Company
24th Feb 20172:28 pmRNSExercise of Options and Total Voting Rights
24th Feb 201712:20 pmRNSHolding(s) in Company
21st Feb 20177:00 amRNSExercise of Options and Total Voting Rights
1st Feb 201711:44 amRNSHolding(s) in Company
26th Jan 20178:29 amRNSDividend Timetable
24th Jan 20177:01 amRNSDirectorate Changes
24th Jan 20177:00 amRNSInterim Results
9th Dec 20167:00 amRNSAcquisition of IPI Solutions Ltd
7th Dec 20162:14 pmRNSHolding(s) in Company
28th Nov 20164:55 pmRNSHolding(s) in Company
24th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 201611:37 amRNSHolding(s) in Company
7th Nov 20167:00 amRNSTrading Update
2nd Nov 20167:00 amRNSExercise of Options and Total Voting Rights
28th Oct 20161:26 pmRNSResult of AGM
13th Oct 20167:00 amRNSNew Contract Wins worth £1.2m
11th Oct 20167:00 amRNSExercise of Options and Total Voting Rights
6th Oct 20167:00 amRNSNotice of AGM
6th Sep 20167:00 amRNSAcquisition of Logen Ltd.
1st Sep 20167:00 amRNSExercise of Options and Total Voting Rights
12th Aug 20167:00 amRNSExercise of Options and Total Voting Rights
8th Aug 20167:00 amRNSAcquisition of Covalent Software Ltd
29th Jul 20167:00 amRNSExercise of Options and Total Voting Rights
19th Jul 20163:28 pmRNSDividend Timetable
19th Jul 20167:00 amRNSFinal Results
12th Jul 20167:00 amRNSNotice of Results
5th Jul 20167:00 amRNSHolding(s) in Company
29th Jun 20161:56 pmRNSHolding(s) in Company
18th May 20167:00 amRNSPre-Close Trading Update
5th May 20167:00 amRNSExercise of Options and Total Voting Rights
29th Apr 20167:00 amRNSNew contract wins in life science sector
29th Mar 20167:00 amRNSExercise of Options and Total Voting Rights
18th Mar 20167:00 amRNSRe £4.9m Contract and Trading Update
29th Jan 20168:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.